KR20240130085A - 트리시클릭 유도체 억제제, 이의 제조 방법 및 응용 - Google Patents

트리시클릭 유도체 억제제, 이의 제조 방법 및 응용 Download PDF

Info

Publication number
KR20240130085A
KR20240130085A KR1020247020514A KR20247020514A KR20240130085A KR 20240130085 A KR20240130085 A KR 20240130085A KR 1020247020514 A KR1020247020514 A KR 1020247020514A KR 20247020514 A KR20247020514 A KR 20247020514A KR 20240130085 A KR20240130085 A KR 20240130085A
Authority
KR
South Korea
Prior art keywords
alkyl
cyano
cycloalkyl
aryl
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247020514A
Other languages
English (en)
Korean (ko)
Inventor
지엔루이 우
지아창 뚱
팡팡 찐
원성 위
리프우 장
Original Assignee
상하이 한서 바이오메디컬 컴퍼니 리미티드
장쑤 한서 파마슈티칼 그룹 캄파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 한서 바이오메디컬 컴퍼니 리미티드, 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 filed Critical 상하이 한서 바이오메디컬 컴퍼니 리미티드
Publication of KR20240130085A publication Critical patent/KR20240130085A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247020514A 2021-12-30 2022-12-29 트리시클릭 유도체 억제제, 이의 제조 방법 및 응용 Pending KR20240130085A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202111655759.X 2021-12-30
CN202111655759 2021-12-30
CN202210249052 2022-03-14
CN202210249052.7 2022-03-14
CN202211064934 2022-08-31
CN202211064934.2 2022-08-31
PCT/CN2022/143665 WO2023125877A1 (zh) 2021-12-30 2022-12-29 三并环类衍生物抑制剂、其制备方法和应用

Publications (1)

Publication Number Publication Date
KR20240130085A true KR20240130085A (ko) 2024-08-28

Family

ID=86998069

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247020514A Pending KR20240130085A (ko) 2021-12-30 2022-12-29 트리시클릭 유도체 억제제, 이의 제조 방법 및 응용

Country Status (11)

Country Link
US (1) US20250059196A1 (https=)
EP (1) EP4458819A4 (https=)
JP (1) JP2025501056A (https=)
KR (1) KR20240130085A (https=)
CN (1) CN118451068A (https=)
AU (1) AU2022425324A1 (https=)
CA (1) CA3242194A1 (https=)
IL (1) IL313925A (https=)
MX (1) MX2024008008A (https=)
TW (1) TW202333682A (https=)
WO (1) WO2023125877A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515550A (zh) * 2023-06-29 2025-04-16 大陸商上海翰森生物醫藥科技有限公司 三并環類抑制劑與抗癌劑在製備抗腫瘤藥物中的聯合應用
CN121285553A (zh) * 2023-06-29 2026-01-06 上海翰森生物医药科技有限公司 一种三并环类衍生物抑制剂的晶型及其制备方法
CN117534669A (zh) * 2023-11-01 2024-02-09 上海凌凯医药科技有限公司 五元氮杂环并吡啶醇的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667303B1 (en) 2001-07-30 2003-12-23 Wyeth Aryl substituted 1,4-diazepanes and method of use thereof
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
EA201590916A1 (ru) 2012-11-09 2016-02-29 Корнэлл Юниверсити Низкомолекулярные ингибиторы malt1
SG11201607895PA (en) 2014-05-28 2016-12-29 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
US9812645B2 (en) 2015-02-13 2017-11-07 Flexterra, Inc. Perylene-based semiconductors
WO2017057695A1 (ja) 2015-09-30 2017-04-06 東レ株式会社 ジフェニルピラゾール誘導体及びその医薬用途
AU2016352813B2 (en) 2015-11-13 2019-09-19 Novartis Ag Novel pyrazolo pyrimidine derivatives
US10662156B2 (en) 2016-07-29 2020-05-26 Toray Industries, Inc. Guanidine derivative and medical use thereof
PE20190656A1 (es) 2016-07-29 2019-05-08 Lupin Ltd Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
US10689366B2 (en) 2016-11-01 2020-06-23 Cornell University Compounds for MALT1 degredation
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
WO2018159650A1 (ja) 2017-02-28 2018-09-07 東レ株式会社 グアニジン誘導体及びその医薬用途
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
JPWO2019039429A1 (ja) 2017-08-22 2020-07-30 日本曹達株式会社 環状アミン化合物および有害生物防除剤
AU2019289222B2 (en) * 2018-06-18 2023-07-13 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
EP3810609B1 (en) * 2018-06-18 2024-06-12 Janssen Pharmaceutica NV Pyrazole derivatives as malt1 inhibitors
KR20210069079A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
TWI848400B (zh) 2018-11-28 2024-07-11 日商武田藥品工業股份有限公司 雜環化合物及醫藥
CN109665987B (zh) * 2018-12-28 2022-02-18 河南大学 萘内酰亚胺-多胺缀合物及其制备方法和用途
US20220175760A1 (en) * 2019-02-22 2022-06-09 Janssen Pharmaceutica Nv Pharmaceutical formulations
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
TW202106684A (zh) 2019-05-03 2021-02-16 美商奇奈特生物製藥公司 Raf激酶抑制劑
CN112125885B (zh) * 2019-06-25 2026-03-17 中国药科大学 苯并吲哚类双功能分子衍生物及其应用
CN116723839A (zh) 2020-10-14 2023-09-08 C4医药公司 用于降解靶蛋白质的三环杂双官能化合物
CA3194351A1 (en) 2020-10-14 2022-04-21 Christopher G. Nasveschuk Tricyclic compounds to degrade neosubstrates for medical therapy
WO2022089406A1 (zh) 2020-10-26 2022-05-05 上海青煜医药科技有限公司 含氮稠杂环类化合物及其制备方法和应用
CN114907358A (zh) * 2021-02-09 2022-08-16 上海翰森生物医药科技有限公司 含吡啶多环类衍生物调节剂、其制备方法和应用
BR112023017689A2 (pt) * 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
TW202317537A (zh) * 2021-06-18 2023-05-01 大陸商上海拓界生物醫藥科技有限公司 一種malt 1抑制劑及其製備方法和用途

Also Published As

Publication number Publication date
EP4458819A1 (en) 2024-11-06
JP2025501056A (ja) 2025-01-17
AU2022425324A1 (en) 2024-05-30
CA3242194A1 (en) 2023-07-06
EP4458819A4 (en) 2026-01-07
CN118451068A (zh) 2024-08-06
WO2023125877A1 (zh) 2023-07-06
MX2024008008A (es) 2024-07-12
US20250059196A1 (en) 2025-02-20
TW202333682A (zh) 2023-09-01
IL313925A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
AU2017382185C9 (en) Pyrazole derivatives as MALT1 inhibitors
AU2017221802B2 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
AU2017228385B2 (en) Substituted indole Mcl-1 inhibitors
KR20240130085A (ko) 트리시클릭 유도체 억제제, 이의 제조 방법 및 응용
AU2022261029A1 (en) Heterocyclic derivative inhibitor and preparation method therefor and application thereof
WO2021130731A1 (en) Substituted tricyclic compounds
KR102187811B1 (ko) Ｓｓａｏ 억제제로서 이미다조[4,5-ｃ]피리딘 및 피롤로[2,3-ｃ]피리딘 유도체
TW201121973A (en) Substituted N-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors
AU2014249003A1 (en) Novel compounds and compositions for inhibition of FASN
RS58014B1 (sr) Triciklična jedinjenja kao antikancerski agensi
EP3307740B1 (en) 5h-pyrido[3,2-b]indole compounds as anticancer agents
JP2023527487A (ja) Ｅｎｌ／ａｆ９ ｙｅａｔｓの阻害剤
AU2019379213A1 (en) Six-membered fused with six-membered heterocyclic compound and uses thereof serving as protein receptor kinase inhibitor
KR20250169597A (ko) 벤조 융합 고리계 화합물 억제제, 및 이의 제조 방법과 응용
RU2827641C1 (ru) Замещенные трициклические соединения
CA3288576A1 (en) Benzo-fused ring compound inhibitor, and preparation method therefor and use thereof
TW202610638A (zh) 包含維爾納症候群解旋酶抑制劑之組成物及其使用方法
AU2016259396A1 (en) Substituted triazoles useful as Axl inhibitors
NZ708137B2 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240619

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application